ReviewHepatology (Baltimore, Md.)2021
Epidemiology of Hepatocellular Carcinoma.
Review in Hepatology (Baltimore, Md.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,294 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,294 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Clinical and Epidemiologic Characteristics of Patients with Hepatocellular Carcinoma in South Asia: A Systematic Review and Meta-analysis.Journal of gastrointestinal cancer · 2026Pooled it
- A systematic review of comparisons of AI and radiologists in the diagnosis of HCC in multiphase CT: implications for practice.Japanese journal of radiology · 2026Pooled it
- Performance of Artificial Intelligence Models in Predicting Responsiveness of Hepatocellular Carcinoma to Transarterial Chemoembolization (TACE): A Systematic Review and Meta-Analysis.Journal of the American College of Radiology : JACR · 2026Pooled it
- Prevention, surveillance, and early detection of hepatocellular carcinoma - a Brazilian multidisciplinary consensus.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2026Guideline
- Efficacy and safety of AiDi injection in treating primary liver cancer: a systematic review on 70 randomized controlled trials.Scientific reports · 2025Pooled it
- Evaluating robotic vs. laparoscopic liver resection for BCLC stage 0-I hepatocellular carcinoma: a meta-analysis of propensity score-matched studies on perioperative outcomes.Journal of robotic surgery · 2025Pooled it
- Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial.Liver international : official journal of the International Association for the Study of the Liver · 2025Trial
- Balloon-Occlusion Versus End-Hole Transarterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.Cardiovascular and interventional radiology · 2026Review
- Combining antiviral therapy with cancer treatment in HBV-associated HCC: A translational approach.Virus research · 2026Review
- Healthcare Utilization and Direct Medical Costs of Hepatocellular Carcinoma Treatment - A German Claims Data Study of 2778 Patients.PharmacoEconomics - open · 2026Article
- Biohybrid nanovesicle-mediated targeted delivery of HSP90 inhibitor for enhanced sorafenib therapy of hepatocellular carcinoma after radiofrequency ablation.Materials today. Bio · 2026Article
- Global disparities in hepatocellular carcinoma care: insights from the ESGAR Global Abdominal Imaging Forum.European radiology · 2026Article
- Aflatoxin-associated hepatocarcinogenesis in a changing climate: the gut microbiome as a missing link in the One Health framework.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- From kidney to liver: Are sodium-glucose cotransporter-2 inhibitors emerging as metabolic disease modifiers?World journal of nephrology · 2026Article
- Trends in Comorbidities and Fatalities Among First-Time Hepatitis B Hospitalizations in Poland (2012-2023).Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- METTL3 promotes proliferation and invasion and inhibits ferroptosis in hepatocellular carcinoma by mediating m6A methylation modification of NUPR1.Molecular and cellular biochemistry · 2026Article
- Processing enhances the anti-hepatocellular carcinoma effect of Momordicae Semen via remodeling chemical composition and regulating the Akt/mTOR/STAT3 pathway.Biochemistry and biophysics reports · 2026Article
- The Emerging Challenge of Non-Cirrhotic MASLD-Related Hepatocellular Carcinoma: Etiology, Immunopathology, and Precision Oncology.Liver cancer · 2026Review
- Barriers to Hepatitis B Treatment: A Multicentre Cross-Sectional Registry and Survey Study by the Canadian Hepatitis B Network.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Psychological Stress Promotes Tumor Growth in Hepatocellular Carcinoma Models Through Myeloid Signaling.Cancer science · 2026Article
1,234 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Liver cancer is a major contributor to the worldwide cancer burden. Incidence rates of this disease have increased in many countries in recent decades. As the principal histologic type of liver cancer, hepatocellular carcinoma (HCC) accounts for the great majority of liver cancer diagnoses and deaths. Hepatitis B virus (HBV) and hepatitis C virus (HCV) remain, at present, the most important global risk factors for HCC, but their importance will likely decline in the coming years. The effect of HBV vaccination of newborns, already seen in young adults in some countries, will be more notable as vaccinated cohorts age. In addition, effective treatments for chronic infections with both HBV and HCV should contribute to declines in the rates of viral-associated HCC. Unfortunately, the prevalence of metabolic risk factors for HCC, including metabolic syndrome, obesity, type II diabetes and non-alcoholic fatty liver disease (NAFLD) are increasing and may jointly become the major cause of HCC globally. Excessive alcohol consumption also remains an intractable risk factor, as does aflatoxin contamination of food crops in some parts of the world. While significant efforts in early diagnosis and better treatment are certainly needed for HCC, primary prevention efforts aimed at decreasing the prevalence of obesity and diabetes and controlling mycotoxin growth, are just as urgently required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.